Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542399 | 0.77 | MEN1 (0.64) | LMNAMMP2MMP3MMP9MEN1 | |
| SCHEMBL2444131 | 0.73 | THRA (0.43) | LMNASMN1; SMN2GPBAR1CYSLTR2CYSLTR1 | |
| SCHEMBL542606 | 0.72 | MEN1 (0.64) | LMNAMMP2MMP3MMP9MEN1 | |
| SCHEMBL2443182 | 0.71 | THRA (0.52) | MAOB | |
| SCHEMBL2443183 | 0.71 | MAOB (0.42) | GPBAR1CYSLTR2CYSLTR1CA12CA1 | |
| SCHEMBL2440843 | 0.69 | ALOX5 (0.44) | LMNAMEN1KMT2ASMN1; SMN2GPBAR1 | |
| SCHEMBL2440845 | 0.69 | MEN1 (0.44) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL7880640 | 0.68 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2GPBAR1CYSLTR2 | |
| SCHEMBL10642885 | 0.68 | NR5A1 (0.62) | CA12CA1CA2CA3CA4 | |
| SCHEMBL347683 | 0.68 | NR5A1 (0.62) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-01-04 | — | — | US | disclosed |
| US-9708353-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2364089-B1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9181191-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2015-08-20 | — | — | US | disclosed |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2014-04-10 | — | — | US | disclosed |
| US-8349849-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2364089-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2010051031-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | LMNA 3054/4885MMP2 4854/4885MMP3 4550/4885 |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | LMNA 3054/4885MMP2 4854/4885MMP3 4550/4885 |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | LMNA 3054/4885MMP2 4854/4885MMP3 4550/4885 |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | LMNA 3054/4885MMP2 4854/4885MMP3 4550/4885 |
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | LMNA 3054/4885MMP2 4854/4885MMP3 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.